熱門資訊> 正文

Axsome因Auvelity处方数据而上涨

2026-09-12 01:25

Axsome Therapeutics (AXSM) is up ~6% in Friday trading following data showing that prescriptions for Auvelity (dextromethorphan and bupropion) reached a record high.
Data from Symphony Health, part of HealthVerity, found that scripts for the depression and Alzheimer's disease agitation treatment reached hit ~23,500 this week.
The US FDA granted the Alzheimer's agitation indication in late April.
Mizuho analyst Graig Suvannavejh, who rates Axsome at outperform, said that "while still early days in the launch, this appears highly indicative of a strong start for Auvelity in ADA."

More on Axsome Therapeutics

Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
Axsome signals 1 NDA per year through 2030 as AXS-12 targets May 1, 2027 PDUFA
Axsome Therapeutics Q2 2026 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。